Trial Profile
Phase III trial to compare the immunogenicity of hepatitis B vaccine 1018-ISS conjugate with that of recombinant hepatitis B vaccine in adults 40-70 years of age.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Mar 2012
Price :
$35
*
At a glance
- Drugs Adjuvanted Hepatitis-B vaccine (Recombinant)-Dynavax (Primary) ; Hepatitis B vaccine recombinant
- Indications Hepatitis B
- Focus Pharmacodynamics; Therapeutic Use
- 13 Feb 2012 Results published in Vaccine.
- 19 Sep 2007 Results have been reported at ICAAC 2007.
- 30 Nov 2006 Status change